Toggle light / dark theme

Medical researchers in the Republic of the Congo have discovered that an Israeli-developed HIV drug apparently can be used to successfully treat critically ill COVID-19 patients. Furthermore, the drug might be available within “weeks to months, but not more” after further clinical trials are carried out.

Doctors from the Clinique La Source hospital in the Congolese capital Brazzaville noted that HIV patients who were in critical condition due to COVID-19 showed significant improvement after being administered a drug named Gammora for their HIV symptoms.


Local researchers in Republic of the Congo note improvement among HIV patients with COVID-19, conduct small trial that confirms outcome.

#FoxNews


U.S. Surgeon General Dr. Jerome Adams explains why the CDC and WHO do not recommend the general public wear masks and how doing so could increase your virus risk.

Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.

U.S. Surgeon General Jerome Adams said on “Fox & Friends” Tuesday that “the data doesn’t show” that wearing masks in public will help people during the coronavirus pandemic.

The choices we make today, and it’s consequences will shape up this decade. Can we break the current pattern, engage with this new financial system and adapt to new realities? #blockchain


As human beings, we are defined by patterns. Our collective pattern defines society. We are empowered with choices – furthering the patterns, or breaking them or creating new ones. In the physical world, these choices could be social, economic, technological, or ecological. Based on the choices we make – good, bad, or ugly, we enjoy or suffer consequences. COVID-19 escalated the macroeconomic situation leading to liquidity, demand, and supply shocks. Can we break the current pattern and embrace digitization, decentralization and sound money? In turn, making choices that will create affirmative consequences for humanity.

Patterns, Choices & Consequences

On the late evening of 5th July 2004, one of our core team members was driving on Mumbai – Pune highway in a Maruti 800, after an offsite monthly sales review in Mumbai (India). He had to be in Pune for an early morning sales leadership training program. It was getting dark and he was trying his best to get out of Mumbai traffic onto the expressway. Once he reached the expressway, he felt it would be a breeze to get to Pune. This was his usual circuit and he was cruising at about 80 km per hour (not high speed or rash driving by any standards). He was ambitious. Past midway the weather conditions suddenly changed and it started pouring with no visibility beyond two feet. He pushed the accelerator trying to overtake a bus. He hadn’t bothered to check that the tyres were worn out and there was mud sludge on the road. He was ill-prepared and complacent. This lethal combination made his car lose control, spinning and toppling and diving next to a waterlogged canal.

Aubrey De Grey and Reason from ’ Fight Aging’:


How can the current public focus on health be leveraged to promote a focus on prevention of disease, and aging as root cause for diseases?

Ole mensching, apollo ventures aubrey de grey, SENS research foundation sonia arrison, 100 plus capital reason, fightaging

Indeed, the coronavirus pandemic has wreaked havoc on research around the globe, shuttering laboratories, aborting field projects, and costing scientists months—if not years—of work. Even as labs contemplate reopening—if and when federal and local governments ease lockdown restrictions—the challenges will be enormous. Most will have to operate with just a few individuals at a time, working in shifts. All large gatherings, including lab meetings and lectures, are likely to be prohibited. And there will be stark differences in strategy between fields—and sometimes even within the same building. At the same time, many institutions are still trying to figure out how and whether to test employees for SARS-CoV-2, the coronavirus causing the current pandemic, and what to do if infections resurge.


Institutions struggle with—and differ on—the best way to restart science.

An international research team has identified the mechanism behind one of science’s most enduring mysteries: what makes the 100-year-old tuberculosis (TB) vaccine so effective at preventing newborn deaths from diseases other than TB?

The ability of Bacillus Calmette-Guérin (BCG)—one of the oldest, safest and cheapest vaccines available—to provide protection to newborns beyond its intended purpose of fighting off TB has been known since at least the 1940s, but until now no one has been able to explain why or show how it works.

In a new study, published today in Science Translational Medicine, researchers reveal how they identified a dramatic and rapid increase in neutrophils— that patrol the body and destroy invading bacterial pathogens—in mice and babies within three days of BCG vaccination.